AVR 1.91% $18.00 anteris technologies ltd

Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-114

  1. 26,725 Posts.
    lightbulb Created with Sketch. 1732
    View it as a bio-tech start-up with $22M in start-up funds looking at developing a new medical product (TAVR) so expenditure should be back to the old AHZ days of $4M per year......dreaming?
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.